Combination Statin and Ezetimibe Therapy May Become Recent “Gold Standard” in Preventing Cardiovascular Deaths
A large-scale analysis indicates that patients at very high cardiovascular risk, or those who have already experienced a myocardial infarction (heart attack), may benefit from starting treatment with both statins and ezetimibe, rather than statins alone. Experts suggest this approach could prevent hundreds of thousands of deaths annually worldwide, according to Mirror.
Published in the scientific journal Mayo Clinic Proceedings, a new study is shifting perspectives on the treatment of “bad” cholesterol (LDL-C). The research, the most extensive of its kind to date, suggests that combining statins and ezetimibe should become the standard of care for individuals facing a significantly elevated cardiovascular risk. This finding is particularly key given the global burden of cardiovascular disease and the need for effective preventative strategies.
Key Findings of the Analysis
Researchers analyzed data from 14 clinical studies encompassing 108,353 patients with an increased risk of heart attack or stroke, or who had already experienced one of these events.
The results demonstrate that when ezetimibe was added to a high-dose statin, the risk of death from any cause decreased by 19% compared to treatment with a high-dose statin alone.
the analysis revealed:
- Cardiovascular deaths were reduced by 16%
- Major cardiovascular events decreased by 18%
- The risk of stroke was reduced by 17%
the combined therapy lowered LDL cholesterol levels by an additional 13 mg/dL compared to statins used individually, and increased the likelihood of reaching the recommended target of under 70 mg/dL by 85%.
Even More Significant Reductions in Expanded Analysis
Maciej Banach, professor at the John Paul II Catholic University of Lublin and the study’s lead author, stated that an extended comparative analysis showed even more impressive results:
- A 49% reduction in mortality from all causes
- A 39% reduction in major cardiovascular events
According to the researcher, the combined therapy proved safe, with adverse event rates and treatment discontinuation rates comparable to, or even lower than, those observed with high-dose statin treatment alone.
Why This Shift in Approach Matters
Current medical guidelines typically recommend initiating treatment with statins and evaluating the results after one to two months before considering the addition of ezetimibe. However, the study authors argue that this delay could have life-threatening consequences.
Peter Toth, a co-author of the study from the University of Illinois, explained that immediately adding ezetimibe to statin therapy, without waiting for the effects of monotherapy, significantly increases the chances of quickly achieving optimal cholesterol levels and reducing the risk of serious complications.
A major benefit of this strategy is that it does not require new or expensive medications, but rather optimizes existing treatments.
Global Impact: Hundreds of Thousands of Lives Could Be Saved
Cardiovascular diseases cause approximately 20 million deaths annually worldwide, with 4.5 million linked to elevated LDL-C levels.
Researchers estimate that incorporating the combined therapy into international guidelines could prevent:
- over 330,000 deaths annually among patients who have already had a heart attack
- approximately 50,000 deaths annually in the United States alone
How the Two Medications Work
Statins reduce cholesterol production in the liver, thereby lowering LDL-C levels in the blood.
Ezetimibe works differently, blocking the absorption of cholesterol in the intestine, reducing the amount derived from dietary sources.
Experts summarize the new strategy with two key principles: “lower is better” and “earlier is better.”
